SC2.0 More Details »
Click for More...
for gene synthesis, only 2 days and $49
Free gRNA design $199/construct
Gene Synthesis supports the development of
Therapeutic antibodies, specifically
monoclonal antibodies, can activate, repress, or alter endogenous immune responses to specific cells or molecules. Antibody-based drugs are revolutionizing the treatment of cancer, inflammatory and autoimmune disease, and many other types of disease.
Genscript is the only company providing end-to-end antibody drug development. Gene Synthesis provides key advantages throughout the process of
Antibody Drug Development:
From custom bioreagents to antibody drug developments, GenScript offers a comprehensive range of services to aid in basic and translational biomedical research as well pharmaceutical research & development.
Gene Synthesis can help you:
Peptide Services offer:
Antibody Services offer:
Antibody Drug Development Center offer
Read more about how gene synthesis is playing a role in research and development of:
In contrast to antibodies used in cancer therapeutics, which aim to stimulate an immune attack, therapeutic antibodies for inflammatory and autoimmune diseases are designed to do the opposite: neutralizing antibodies bind to pro-inflammatory factors and prevent them from exacerbating the immune response. Two recently published studies developed antibodies to minimize FcR-mediated immune responses with the benefit of
gene synthesis of full-length or truncated DNA sequences encoding immunoglobulin chains, Fc receptors, and other components of inflammatory signaling:
Therapeutic Monoclonal Antibodies (mAbs) are the market leader in the targeted cancer therapy space; include blockbusters trastuzumab (Herceptin®) and rituximab (Rituxan®). Monoclonal antibody therapy regimens may target tumor-specific antigens/receptors, or may block important pathways central to tumor growth and survival.
Read about monoclonal antibodies developed using gene synthesis and antibody services from GenScript:
Methods Mol Biol. 2013 Sep.
Humanization and Simultaneous Optimization of Monoclonal Antibody Methods
PLoS One. 2013 Jan.
Isolation of a High Affinity Neutralizing Monoclonal Antibody against 2009 Pandemic H1N1 Virus
Antibody-drug conjugates use mAbs to target cytotoxic drugs specifically to cancer cells. For example, brentuximab vedotin (Adcetris™) for Hodgkin lymphoma combines an anti-CD30 monoclonal antibody + the cytotoxic agent monomethyl auristatin E (MMAE) which is released only upon internalization into CD30+ cancer cells.
Read about antibody-drug conjugates developed using services from GenScript:
Antibody drug development is not always straight-forward, but GenScript's gene synthesis and antibody engineering services can help overcome the challenges.
A protein expressed only by cancer cells and not by healthy cells can help avoid dangerous widespread autoimmunity. Targeting an immune checkpoint protein or a receptor that is manipulated by cancer cell signaling can help to overcome cancer-induced immunosuppression, e.g. CTLA-4 or PD-1.
Types of Antigens used for antibody drug development include:
Gene synthesis enables:
Monoclonal antibody production methods, such as
hybridoma development, give us the ability to derive individual antibodies of invariant specificity and selectivity and to immortalize the antibody-producing cells, ensuring a virtually infinite supply of highly specific antibodies. However, hybridoma technology requires substantial time, labor, expertise, specialized cell culture facilities, lab animals, and the screening of large numbers of hybridomas. The number of substances that are immunogenic in mammals is limited, and the maximum diversity expected from the mammalian immune response is on the order of 6 x 106 different antibodies. More importantly, there is no practical way to alter the properties of antibodies produced by hybridomas.
These challenges may be overcome through the use of
hybrid chimeric antibodies in which the mouse variable and human constant regions are fused on a genetic level. Recombinant human-mouse antibodies of this nature retain the specificity of the original murine variable region but assume the effector function of the human constant region.
Gene synthesis enables
Antibody sequencing enables further engineering of the antibody for optimization, and insures against loss of hybridomas.
Antibody affinity maturation with phage display library enables fast screening to obtain antibodies with high specificity against the target antigen.
Antibody humanization enables chimerization of a monoclonal antibody, translating it into an antibody therapeutic that can be used in humans.
Chimeric molecules that combine immune-stimulatory cytokines with cancer-targeted antibodies can induce an effective localized immune response.
GenScript has been on the forefront of supporting the development of therapeutic antibodies. Read the featured studies below, or
search more than 8,400 Peer Reviewed Publications that cite GenScript.
The products and services in this section are for Research Use Only. Not for use in human clinical diagnostics or therapeutics or in vitro diagnostic procedures.
Please contact us if you need immediate assistance.
Please contact us (phone: 1-877-436-7274 or email: firstname.lastname@example.org),if you need immediate assistance.